VolitionRx's Announces Positive Preliminary Findings for Colon, Breast and Lung Cancer Diagnostic Tests
VolitionRx (OTC: VNRX)today announced preliminary findings from its ongoing internal clinical trials of the NuQ® diagnostic platform. VolitionRx has analysed blood samples from 105 patients and was able to detect 76% of the patients with colon cancer, 96% of those with breast cancer, and 100% of patients with lung cancer.
Of the 105 patients tested, 74 had cancer (25 colon cancer, 25 breast cancer and 24 lung cancer), and 31 were healthy (not diagnosed with cancer). Volition tested all the patient samples for elevated nucleosome structures using one of its NuQ kits, with the following results for colon, breast and lung cancer:
Colon: 76% of cancers detected (19 of 25 patients) and 90% specificity (3 false positives from 31 healthy samples)
Breast: 96% of cancers detected (24 of 25 patients) and 90% specificity (3 false positives from 31 healthy samples)
Lung: 100% of cancers detected (24 of 24 patients) and 79% specificity (6 false positives from 28 healthy samples).
Further clinical results will be announced as they become available.
As announced in July, VolitionRx is currently moving through an independent 800-patient (expanded from the initial 400